These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87 related articles for article (PubMed ID: 10213206)
21. A dose escalation study of docetaxel and oxaliplatin combination in patients with metastatic breast and non-small cell lung cancer. Kouroussis C; Agelaki S; Mavroudis D; Kakolyris S; Androulakis N; Kalbakis K; Souglakos J; Mallas K; Bozionelou V; Pallis A; Adamtziki H; Georgoulias V Anticancer Res; 2003; 23(1B):785-91. PubMed ID: 12680184 [TBL] [Abstract][Full Text] [Related]
22. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes. Pentheroudakis G; Briasoulis E; Karavassilis V; Mauri D; Tzamakou E; Rammou D; Pavlidis N Chemotherapy; 2005 May; 51(2-3):154-61. PubMed ID: 15886476 [TBL] [Abstract][Full Text] [Related]
23. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas. Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154 [TBL] [Abstract][Full Text] [Related]
24. A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children's Oncology Group experience. Angiolillo AL; Davenport V; Bonilla MA; van de Ven C; Ayello J; Militano O; Miller LL; Krailo M; Reaman G; Cairo MS; Clin Cancer Res; 2005 Apr; 11(7):2644-50. PubMed ID: 15814645 [TBL] [Abstract][Full Text] [Related]
25. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics. Morgan RJ; Doroshow JH; Synold T; Lim D; Shibata S; Margolin K; Schwarz R; Leong L; Somlo G; Twardowski P; Yen Y; Chow W; Lin P; Paz B; Chu D; Frankel P; Stalter S Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5896-901. PubMed ID: 14676112 [TBL] [Abstract][Full Text] [Related]
26. Update: the M.D. Anderson Cancer Center experience with paclitaxel in the management of breast carcinoma. Holmes FA Semin Oncol; 1995 Aug; 22(4 Suppl 8):9-15. PubMed ID: 7543702 [TBL] [Abstract][Full Text] [Related]
27. Phase I and pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumors. Bhalla KN; Kumar GN; Walle UK; Ibrado AM; Javed T; Stuart RK; Reed C; Arbuck SG; Walle T Clin Cancer Res; 1999 Jul; 5(7):1723-30. PubMed ID: 10430075 [TBL] [Abstract][Full Text] [Related]
28. Study of dose escalation and sequence switching of administration of the combination of docetaxel and doxorubicin in advanced breast cancer. Itoh K; Sasaki Y; Fujii H; Minami H; Ohtsu T; Wakita H; Igarashi T; Watanabe Y; Onozawa Y; Kashimura M; Ohashi Y Clin Cancer Res; 2000 Oct; 6(10):4082-90. PubMed ID: 11051260 [TBL] [Abstract][Full Text] [Related]
29. Phase I evaluation of docetaxel and topotecan for patients with advanced solid tumors. Tsao AS; Shin DM; Palmer JL; Lee JS; Glisson BS Cancer; 2004 May; 100(10):2240-5. PubMed ID: 15139070 [TBL] [Abstract][Full Text] [Related]
30. Docetaxel in combination chemotherapy for metastatic breast cancer. Khayat D; Antoine E Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-19-S13-26. PubMed ID: 9335513 [TBL] [Abstract][Full Text] [Related]
31. Phase I trial of a 96 h paclitaxel infusion with filgrastim support in refractory solid tumor patients. Socinski MA; Mudd PN; Radomski KM; Steagall A; Lawrence P; Bernard S; Letrent SP; Gonzalez P; Brouwer KL Anticancer Drugs; 1998 Aug; 9(7):611-9. PubMed ID: 9773805 [TBL] [Abstract][Full Text] [Related]
32. The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel. van Zuylen L; Sparreboom A; van der Gaast A; van der Burg ME; van Beurden V; Bol CJ; Woestenborghs R; Palmer PA; Verweij J Clin Cancer Res; 2000 Apr; 6(4):1365-71. PubMed ID: 10778964 [TBL] [Abstract][Full Text] [Related]
33. Biweekly docetaxel in recurrent ovarian cancer: a phase I dose finding study. Mäenpää J; Leminen A Cancer Chemother Pharmacol; 2009 Jul; 64(2):297-300. PubMed ID: 19020876 [TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors. Zamboni WC; Egorin MJ; Van Echo DA; Day RS; Meisenberg BR; Brooks SE; Doyle LA; Nemieboka NN; Dobson JM; Tait NS; Tkaczuk KH J Clin Oncol; 2000 Sep; 18(18):3288-94. PubMed ID: 10986062 [TBL] [Abstract][Full Text] [Related]
35. Phase I and pharmacokinetic study of CI-980 in recurrent pediatric solid tumor cases: a Pediatric Oncology Group study. Bernstein ML; Baruchel S; Devine S; Markoglou N; Wainer IW; Williams M; Blaney S; Moghrabi A; Winick N; Vietti T J Pediatr Hematol Oncol; 1999; 21(6):494-500. PubMed ID: 10598660 [TBL] [Abstract][Full Text] [Related]
36. Paclitaxel plus gallium nitrate and filgrastim in patients with refractory malignancies: a phase I trial. Sandler A; Fox S; Meyers T; Christou A; Weber G; Gonin R; Loehrer PJ; Einhorn LH; Dreicer R Am J Clin Oncol; 1998 Apr; 21(2):180-4. PubMed ID: 9537208 [TBL] [Abstract][Full Text] [Related]
37. Phase I study of docetaxel plus ifosfamide in patients with advanced cancer. Marx G; Lewis C; Hall K; Levi J; Ackland S Br J Cancer; 2002 Oct; 87(8):846-9. PubMed ID: 12373597 [TBL] [Abstract][Full Text] [Related]
38. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. Glade Bender JL; Adamson PC; Reid JM; Xu L; Baruchel S; Shaked Y; Kerbel RS; Cooney-Qualter EM; Stempak D; Chen HX; Nelson MD; Krailo MD; Ingle AM; Blaney SM; Kandel JJ; Yamashiro DJ; J Clin Oncol; 2008 Jan; 26(3):399-405. PubMed ID: 18202416 [TBL] [Abstract][Full Text] [Related]
39. [Neutropenia induced by taxoids and its control with granulocyte colony-stimulating factor]. Luis-Fernández J; Rangel-Mayoral JF; Estepa-Alonso MJ; Liso-Rubio FJ Invest Clin; 2005 Sep; 46(3):265-72. PubMed ID: 16152782 [TBL] [Abstract][Full Text] [Related]
40. A phase I and pharmacologic study of pyrazoloacridine and cisplatin in patients with advanced cancer. Dees EC; Rowinsky EK; Noe DA; O'Reilly S; Adjei AA; Elza-Brown K; Donehower RC Invest New Drugs; 2003 Feb; 21(1):75-84. PubMed ID: 12795532 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]